Can you provide a brief overview of your business, its core activities, and how it was founded?
Sciensus is an international life sciences company specialising in market-leading patient access, engagement and insight solutions. With a global presence, we sit proudly at the intersection of patients and their medicine, specifically those with chronic and long-term conditions, rare diseases and cancer. Harnessing the power of more than 70 million patient interactions, captured through our advanced patient support programmes and digital platforms, we uncover vital insight into the patient experience and the drivers of medicine adherence.
Powered by these interactions, we develop and deliver innovative patient interventions and generate invaluable real-world insight to enable clinicians and pharmaceutical companies to drive better outcomes for patients. For 30 years we’ve supported patients to access the life-changing treatment they need. Today, we combine this powerful clinical experience with the latest technology to help more than 240,000 patients a year make the most of their medicine.
Sciensus connects healthcare professionals, pharmaceutical and biotech companies across life sciences with actionable real-world insights to ultimately elevate the patient experience. By enabling faster, more informed decision-making, together with our partners we’re driving better health outcomes for patients across the world.
What key strategies have been implemented in order to drive new revenue growth?
In the past five years, Sciensus has invested heavily in digital transformation. Our strategy focuses on expanding our digitally enabled patient insights offering. Positioned at the intersection of patients and their medicine, we provide access to life-changing treatments and collaborate with healthcare professionals and pharmaceutical partners to deliver vital patient-reported data and insights, improving the patient experience and therapy efficacy. Our apps, portal hubs, and analytics offer stakeholders better visibility into patient health. By understanding therapy use outside clinical settings, we help pharma and care providers personalise and improve care.
Company culture can have a significant impact on revenue. Can you tell me about what your business does to foster a positive workplace culture?
At Sciensus, we work hard to make sure colleagues feel motivated, developed, and recognised for the great work they do. We invest into the personal development of every individual through robust training, and we offer an extensive rewards programme for our people to enjoy alongside their role. We support, encourage and continually develop our teams by offering flexible training programmes for our people to participate in. These cover professional, leadership, and self-development, as well as digital development, continuous improvement and clinical and role-based skills training.
We’re also proud to offer UK funded apprenticeships and support in gaining accredited qualifications to develop our talent and help them achieve their personal development goals.
We are a National Equality Standards accredited employer, marking a major milestone for Sciensus. Through our #BeYou campaign, we’re raising awareness of our equality, diversity and inclusion (EDI) goals and actions to embed these values in our culture, benefiting both colleagues and patients.
Looking ahead, what are your ambitions for growth at your business, and what impact will this have on the way patient care is delivered in the future?
Our leading-edge digital solutions make it easier for patients to manage their treatment, while enabling healthcare professionals and pharmaceutical companies to deliver better medicine-related outcomes.
Our vision is to be the global leader helping each and every patient make the most of their medicine. This means elevating the patient experience and improving the efficacy of patient’s therapy by:
· more personalised support and education
· improved symptom management tools to gather behavioural insights and patient reported data
· enhanced connectivity between patients and HCPs
· enhanced understanding of patient behaviours and drivers of adherence in the real world. In turn these insights will help Pharma to drive innovation in drug development, leading to increased commercial opportunities
· reducing the burden in healthcare systems and improving patient outcomes.
Based on your experience, what advice would you offer to entrepreneurs aiming to start and grow a business?
Although Sciensus has been helping patients make the most of their medicine for more than 30 years, we have continued to innovate our services to become more digitally enabled in order to put patients at the heart of everything we do, whilst getting the basics right.
For entrepreneurs aiming to start their own business, the following will not change whether you are an established company or a growing start up:
Do the basics brilliantly – if you can’t get the basics right for your customers and stakeholders, your business will not have the foundations it needs to succeed or grow.
Know your value play – make sure that your stakeholders feel that they’re getting enough value from you. If they don’t, they will not engage with your brand, and your business proposition will suffer.
Build your business for future growth – if your operational platform is not designed for growth and your digital capabilities are limited, this may restrict your ability to innovate and be nimble enough to be able to pivot and seize new growth opportunities.
Be passionate about your business and your brand – this may sound clichéd, but if you aren’t the biggest believer in your business and what your brand stands for, no one else will believe in it either.
What does it mean to your organisation to be included in the E2E Job Creation 100 list for 2024?
It is wonderful to see Sciensus being recognised alongside other successful UK-based companies. It is a testament to our commitment to fostering innovation and growth, while creating a positive culture that not only strengthens our business but also empowers individuals. This achievement is a proud moment for us, and we look forward to building on this success in the years to come.
For more information and to see the full E2E Dynamic 100 2024 list click here.
Disclaimer: The copyright of this article belongs to the original author. Reposting this article is solely for the purpose of information dissemination and does not constitute any investment advice. If there is any infringement, please contact us immediately. We will make corrections or deletions as necessary. Thank you.
